Startup profile · funding coverage
MiRus funding, valuation and investors
Marietta medtech company commercializing MoRe molybdenum-rhenium alloy implants for spine, orthopedics, and TAVR.
Keep track of MiRus
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Strategic investment
$1.5B · May 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$1.5B
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
growth · Marietta, Georgia, USA
Investors in latest funding
Lead: Boston Scientific
Overview
MiRus LLC, founded in 2015 and headquartered in Marietta, Georgia, develops and commercializes proprietary molybdenum-rhenium (MoRe) biomaterial implants and procedural solutions for spine, orthopedic, and structural heart disease. The MoRe alloy offers higher strength and fatigue resistance than titanium or cobalt-chromium, enabling smaller, more durable implants with a lifetime limited warranty on spinal rods. Commercial spine products include the EUROPA pedicle screw system and Cygnus anterior cervical plating. In cardiovascular, MiRus is developing the SIEGEL balloon-expandable TAVR valve — described as the first nickel-free balloon-expandable TAVR — with encouraging U.S. Early Feasibility Study 30-day results presented at NY Valves 2025. In May 2026, Boston Scientific invested $1.5 billion for approximately 34% equity and an exclusive option to acquire the TAVR business for up to $3 billion upon clinical milestones.
Why MiRus is interesting
MiRus' proprietary MoRe superalloy — inspired by NASA rocket-engine materials science — enables thinner, stronger, nickel-free implants with lower metal-ion release; Boston Scientific's $1.5B strategic stake signals conviction in its SIEGEL TAVR program.
Product & use cases
MiRus manufactures FDA-cleared spine and orthopedic implants from proprietary MoRe molybdenum-rhenium superalloy, plus a developing SIEGEL TAVR valve platform — integrated pre-operative planning, navigation, and post-operative monitoring across the care continuum.
- Posterior and anterior cervical spinal fusion with MoRe rods and pedicle screw systems
- Structural heart: transcatheter aortic valve replacement via SIEGEL low-profile delivery system
- Orthopedic implants requiring higher strength-to-size ratio and reduced metal-ion exposure
- Complex spinal deformity cases where rod fracture rates drive costly revision surgeries
Key facts
- Boston Scientific strategic investment (May 2026): $1.5B for ~34% equity stake — SEC filing, PR Newswire
- Exclusive option for BSX to acquire TAVR business for additional $3B upon clinical/regulatory milestones
- SIEGEL TAVR U.S. EFS: 15 patients, zero deaths/strokes/re-hospitalizations at 30 days (PR Newswire, July 2025)
- MoRe alloy backed by 15+ years R&D — lifetime limited warranty on MoRe spinal rods since 2021
- Spine products include EUROPA pedicle screw system with NTAP add-on payment (CMS)
- Founded by experienced medtech entrepreneurs; MoRe materials inspired by NASA rocket-engine alloy work
Funding history (newest first)
Strategic investment
2026-05 $1.5B- Boston Scientific (lead)
Competitive landscape
Edge: Proprietary MoRe alloy enables thinner-walled, nickel-free implants with superior fatigue resistance and radiopacity — differentiated from titanium and cobalt-chromium incumbents, especially in TAVR hemodynamics.
Medtech megarounds are rare outside AI, but MiRus' $1.5B Boston Scientific deal reflects validated materials science plus a credible TAVR path. Spine revenue provides commercial base while SIEGEL EFS data de-risks the cardiovascular upside — execution on pivotal trials determines whether BSX exercises its $3B acquisition option.
-
Medtronic incumbent
Global spine and TAVR leader (Evolut, CoreValve); MiRus targets differentiation via MoRe alloy and nickel-free SIEGEL design.
-
Edwards Lifesciences incumbent
Dominant TAVR franchise (SAPIEN); MiRus SIEGEL aims for low delivery profile and strong hemodynamics via rhenium alloy frame.
-
Stryker incumbent
Major spine implant portfolio; MiRus competes on MoRe rod durability and lifetime warranty versus conventional titanium systems.
-
Zimmer Biomet incumbent
Broad orthopedic and spine offerings; MiRus differentiates on proprietary alloy science rather than scale.
Notable stories
- MiRus MoRe alloy work traces to NASA rocket-engine refractory metals research — the same molybdenum-rhenium chemistry now used for body-temperature medical implants (MiRus technology page, IMOA industry publication).
- Boston Scientific's $1.5B stake is its third swing at the TAVR market — MiRus' nickel-free SIEGEL valve gives BSX an exclusive option worth up to $3B more if clinical milestones hit (MD+DI, May 2026).
Industries
Related funding articles
Venture Capital Tracker pieces that cover MiRus's financing or category context.
FAQs about MiRus
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.